TLR4 and neoplasm: Additionally, AS1411‐modified chitosan‐ss‐polyethylenimine‐urocanic acid micelles co‐delivering DOX and toll‐like receptor 4 (TLR4) siRNA exhibited excellent tumour targeting, significant anti‐tumour efficacy and enhanced survival rates in tumour‐bearing mice, with low systemic toxicity and improved tumour penetration.91